Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00552851
Recruitment Status : Unknown
Verified September 2010 by University of Wuerzburg.
Recruitment status was:  Recruiting
First Posted : November 2, 2007
Last Update Posted : September 24, 2010
Information provided by:
University of Wuerzburg

Brief Summary:
The purpose of this study is to evaluate changes in left ventricular mass and cardiac function in patients with active acromegaly before and after treatment with the growth hormone receptor antagonist pegvisomant for one year.

Condition or disease Intervention/treatment Phase
Acromegaly Heart Failure Hypertrophy, Left Ventricular Drug: pegvisomant Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 4 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant: an Open-labelled, Prospective Study
Study Start Date : June 2006
Estimated Study Completion Date : December 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hormones
Drug Information available for: Pegvisomant

Arm Intervention/treatment
patients with active acromegaly and impaired cardiac function
Drug: pegvisomant
booster dosage 80 mg once sc., than 10 mg once per day, uptitration in steps of 5 mg up to an IGF-1 level in the normal range (every 4 weeks), max. 30 mg once per day. Duration of treatment: one year
Other Name: Somavert

Primary Outcome Measures :
  1. Change in peak systolic strain rate (SRSYS) determined by Color Doppler Myocardial Imaging (CDMI). [ Time Frame: one year ]

Secondary Outcome Measures :
  1. Ejection fraction,Enddiastolic thickness of the infero-lateral wall,Diastolic function,Left ventricular mass index,Stroke volume,Ejection fraction (MRI),CO,Late hyperenhancement,IGF-I,insulin sensitivity,Ringsize,adverse events,Endothelial function [ Time Frame: one year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Active acromegaly in adult subjects (≥ 18 years) after surgery and/or radiation therapy with elevated IGF-1 levels despite treatment with somatostatin analogues or dopamine agonists
  • Pegvisomant therapy is indicated (i. e. patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapy, or for whom these therapies are not appropriate)
  • Evidence of left ventricular hypertrophy (infero-lateral wall thickness ≥ 12 mm assessed by echocardiography) or
  • Evidence of impaired diastolic function (≥ stage 2 as assessed by echocardiography) or
  • Evidence of systolic dysfunction (Ejection fraction < 50% assessed by echocardiography)
  • Stable medication for arterial hypertension and heart failure for 3 months
  • Written informed consent.

Exclusion Criteria:

  • Pregnancy and lactation period
  • Previous therapy with Pegvisomant
  • Suspected or known hypersensitivity to the drug or any of its components
  • Contraindications for MRI
  • History of malignancy during the last 5 years
  • Suspected or known drug or alcohol abuse
  • Patients who are neither able to self administer study medication on a daily basis nor have a caregiver who can administer study medication to the patient on a daily basis
  • Any condition which in the opinion of the investigator makes the patient unsuitable for inclusion
  • Participation in another clinical trial
  • Pituitary adenoma with a distance to the optic chiasm of < 3 mm
  • Any other drug for treatment of acromegaly (e.g. dopamine agonists, Somatostatin analogues) which would be necessary during the study or patients who apply for radiotherapy
  • Instable heart insufficiency classified as NYHA IV.
  • Severe renal insufficiency, liver transplantation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00552851

Layout table for location contacts
Contact: Gwendolyn Bender, MD 004993120139716
Contact: Bruno Allolio, MD 004993120139020

Layout table for location information
University of Wuerzburg, Department of Endocrinology Recruiting
Wuerzburg, Bavaria, Germany, 97080
Contact: Gwendolyn Bender, MD    004993120139716   
Sponsors and Collaborators
University of Wuerzburg
Layout table for investigator information
Principal Investigator: Bruno Allolio, MD University of Wuerzburg. Department of Endocrinology
Layout table for additonal information
Responsible Party: Prof. Bruno Allolio, Department of Endocrinology Identifier: NCT00552851    
Other Study ID Numbers: NRA 6290010
EudraCT No: 2006-001108-35
First Posted: November 2, 2007    Key Record Dates
Last Update Posted: September 24, 2010
Last Verified: September 2010
Keywords provided by University of Wuerzburg:
heart failure
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Hypertrophy, Left Ventricular
Heart Diseases
Cardiovascular Diseases
Pathological Conditions, Anatomical
Bone Diseases, Endocrine
Bone Diseases
Musculoskeletal Diseases
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases